Alembic's Bosutinib Approval & Market Opportunity

  Published 1 year ago

Alembic Pharmaceuticals received USFDA approval for Bosutinib tablets, a generic equivalent to Bosulif, targeting a $291 million market. Alembic boasts 223 total ANDA approvals and strong R&D/manufacturing capabilities.

  • ANDA approved for Bosutinib, treating CML.
  • $291M US market size (ending March 2025).
  • Alembic: 223 USFDA approvals to date.

You might like these

SBI Accuses Reliance Communications of Loan Fraud

India’s Digital Payments Boom

Kaynes Plans ₹4,995 Cr Investment in TN

Dreamfolks Stock Plummets Amid Airport Operator Rivalry

Germany's Economy Gets a Boost

DBS Bank Forecasts India's Growth, Inflation Outlook

NBCC Bags Major Contracts in India

News that matters the most ⚡